Clinical trials: Anthracyclines
Breast Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm
Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial
This phase II trial compares two drug therapy plans for the correction of heart function changes (reduced ejection function) in patients who have undergone anthracycline-based treatment for lymphoma, sarcoma, or breast cancer.
- Conditions
- Breast Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Sarcoma
- Trial name
- NCT04190433
- Testing
- Carvedilol, Lisinopril, Pravastatin
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
This investigator-initiated, single-arm, phase II trial is aimed to evaluate the efficacy and safety of a venetoclax-based, anthracycline-free regimen in patients with newly diagnosed CBFβ::MYH11-positive acute myeloid leukemia.
- Trial name
- NCT06429098
- Testing
- Venetoclax, azacitidine, decitabine
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
This phase II trial studies how well pembrolizumab and doxorubicin hydrochloride works compared to pembrolizumab with anti-estrogen therapy (anastrozole, letrozole, or exemestane) in treating patients with triple-negative or…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT02648477
- Testing
- Anastrozole, Doxorubicin Hydrochloride, Exemestane
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity
Evaluation of Cardiac and Endothelial Function in Children and Adolescents Treated With Anthracycline
In recent decades, the survival rate of children with cancer has increased significantly thanks to personalized treatments and the adoption of international therapeutic protocols.
- Conditions
- Anthracycline Related Cardiotoxicity in Childhood Cancers, Chemotherapeutic Toxicity, Childhood Cancer Survivors
- Trial name
- CARDIO-PED (NCT07253077)
- Testing
- Biomarker detection
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Prevention of Chemotherapy Induced Ovarian Failure With Goserelin in BC Patients (ZORO)
Study done in young breast cancer patients to prevent chemotherapy induced ovarian failure
- Trial name
- NCT00196846
- Testing
- Goserelin
- Where
- Germany
- Volunteers
- 62 people
- Sponsor
- GBG Forschungs GmbH
Cardiomyopathy Due to Anthracyclines
Stem Cell Injection in Cancer Survivors
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction…
- Trial name
- SENECA (NCT02509156)
- Testing
- Allo-MSCs
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- The University of Texas Health Science Center, Houston
Breast Cancer (Early Breast Cancer), Cardiotoxicity
Cardiac Side Effects of Systemic Therapy in Early-Stage Breast Cancer
The goal of this observational study is to evaluate cardiac side effects in women with early-stage breast cancer who receive systemic chemotherapy and/or anti-HER2 therapy as part of their standard cancer care.
- Conditions
- Breast Cancer (Early Breast Cancer), Cardiotoxicity, Cancer Therapy-Related Cardiac Dysfunction
- Trial name
- C-BREAST-01 (NCT07588425)
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Fatih GURLER
Breast Neoplasms
To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent
To determine the Objective Response Rate of 4 cycles of docetaxel + anthracycline (epirubicin or doxorubicine) followed by 4 cycles of docetaxel single agent.
- Trial name
- NCT00620100
- Testing
- Docetaxel
- Where
- 2 sites in Austria, Poland
- Volunteers
- 2 people
- Sponsor
- Sanofi
Breast Cancer
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer.
- Trial name
- NCT05748834
- Testing
- Tucatinib, Doxil
- Where
- 8 sites in United States
- Volunteers
- 36 people
- Sponsor
- SCRI Development Innovations, LLC
Lymphoma
Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer cell growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00987493
- Testing
- rituximab, bendamustine hydrochloride, lenalidomide
- Where
- 16 sites in Switzerland
- Volunteers
- 49 people
- Sponsor
- Swiss Cancer Institute
HER2 Positive Breast Cancer, Cardiovascular Abnormalities
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
The Cardio-Oncology program at Northwestern offers care to cancer patients who develop cardiac toxicities from chemotherapy. Breast cancer patients with the tumor marker for HER2 necessitate treatment with anthracycline and/or…
- Trial name
- NCT02993198
- Testing
- Carvedilol
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- Northwestern University
Osteosarcoma, Ewing's Sarcoma Family of Tumors
Markers of Anthracycline-Related Cardiac Muscle Injury
Anthracycline antibiotics are included in the chemotherapy regimens of approximately 82% of patients with bone cancer and 44% of those with soft tissue sarcoma diagnosed in childhood or adolescence.
- Conditions
- Osteosarcoma, Ewing's Sarcoma Family of Tumors, Rhabdomyosarcoma, Non-rhabdomyosarcoma Soft Tissue Sarcomas
- Trial name
- NCT01112800
- Sponsor
- St. Jude Children's Research Hospital
Ovarian Cancer
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
The primary objective of this randomized phase II trial is to compare progression-free survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients randomized to an anthracycline alone
- Trial name
- NGR018 (NCT01358071)
- Testing
- NGR-hTNF, Pegylated liposomal doxorubicin, Doxorubicin
- Where
- 8 sites in Italy, United Kingdom
- Volunteers
- 119 people
- Sponsor
- AGC Biologics S.p.A.
Breast Cancer
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003032
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 25 sites in Canada
- Volunteers
- 224 people
- Sponsor
- NCIC Clinical Trials Group
Breast Neoplasms
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Pemetrexed is a multi-targeted anti-folate, that is used for non-small cell lung cancer and mesothelioma. There are several clinical studies of pemetrexed in breast cancer, but these are largely done before the wide use of…
- Trial name
- NCT03242616
- Testing
- Pemetrexed + Vinorelbine, Vinorelbine
- Where
- South Korea
- Volunteers
- 17 people
- Sponsor
- Seoul National University Hospital
Anthracycline-induced Cardiotoxicity
Preventing Cardiac Sequelae in Pediatric Cancer Survivors
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death.
- Trial name
- PCS2 (NCT01805778)
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,128 people
- Sponsor
- The Hospital for Sick Children
Breast Cancer
Oxaliplatin in Treating Women With Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating women who have advanced or…
- Trial name
- NCT00006121
- Testing
- oxaliplatin
- Where
- 10 sites in Austria, Belgium and 5 more
- Volunteers
- 18 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
HER2-negative Breast Cancer
Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer
The study is being conducted to evaluate the efficacy and safety of anlotinib combined with chemotherapy treatment for patients with HER2 negative advanced breast cancer previously received anthracyclines and taxanes
- Trial name
- ALOT-BC1 (NCT05334147)
- Volunteers
- 315 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
ANTthracycline-induced Inflammation and OXidative Stress: 10-year Follow-up
The goal of this observational study is to learn about the long-term effects of anthracycline chemotherapy on inflammation, oxidative stress, and heart function in adult women with breast cancer.
- Conditions
- Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer
- Trial name
- ANTIOX-10 (NCT07680855)
- Volunteers
- 17 people
- Sponsor
- University of Chile
Breast Cancer
NSABP Biospecimen Discovery Project
This study is a biospecimen discovery project that will serve as a pilot for a comprehensive 'omics approach using fresh core biopsy tissue and blood samples for DNA and protein analysis, as well as paired tumor-normal exome DNA…
- Trial name
- NCT01850628
- Testing
- Paclitaxel, trastuzumab, pertuzumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- NSABP Foundation Inc